Pharmafile Logo

Petauri Evidence

We’re excited to announce that Mtech Access has joined forces with Delta Hat as Petauri Evidence. Petauri Evidence is an innovative new business unit within the Petauri platform that unites Mtech Access and Delta Hat, along with Petauri’s US HEOR business. Together, we are dedicated to helping pharmaceutical, biotechnology, and medical device companies generate, apply, and communicate evidence to inform healthcare decision-making.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Resonant Group

Resonant Group is an award-winning group of agencies driven by the same core values and a common belief that lives can be transformed through better health communication.

View Profile

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…

View Profile

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Twelve Marketing

Twelve delivers healthcare communications that drive Change for Good. We support pharma and medtech clients with strategic marketing, behaviour-led campaigns, and purposeful PR, helping teams engage professionals and the public,…

View Profile

Uniphar

Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.

View Profile

Visions4Health

Visions4Health are market access experts and your gateway to local adoption at pace. Leveraging our lived experience, understanding of national and local healthcare systems, and insights generated by our stakeholder…

View Profile

Company Details

Rowood House, Bicester, Oxfordshire, OX26 4PP, United Kingdom
01869 222 490

 Latest Content from PMHub 

The solution: Good localisation doesn’t feel translated

Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every market.

Good Patient Partnership Guide 2026: Patient Journey Mapping with the Patient Community

Patient insight gathering and journey mapping can inform and enhance decision making and initiatives across life sciences. The Good Patient Partnership Guide 2026 brings together practical guidance, real world examples...

Healthcare information is becoming easier to access. Trust isn’t.

Sharing key insights from NEXT Pharma Summit on why trust, clarity and human-centred communication matter more than ever in healthcare.

It was never reluctance: What ASCO 2026 revealed about clinical trial recruitment

ASCO 2026 highlighted that low clinical trial recruitment is driven less by patient reluctance and more by gaps in awareness, communication, accessibility and patient education.

J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment

Press Releases | June 17, 2026 | Uniphar

Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial  TOKYO, Japan and DUBLIN, Ireland — [June 16, 2026] J‑Pharma Co., Ltd., a clinical-stage biotechnology...

Medscape Education Recognized With 2 Spring 2026 Digital Health Awards for Excellence in Clinical Education

Medscape Education has been recognized with 2 prestigious accolades at the Spring 2026 Digital Health Awards. The premier digital education platform earned a Gold Award for its PIONEER initiative in...

How to build a commercialisation strategy fit for biopharma’s new evidence era

The bar for evidence has never been higher. The EU's Joint Clinical Assessment process went live in January 2025, introducing harmonised clinical evidence requirements across member states. Regulators are demanding...

New benchmark reveals significant digital maturity gap across UK POM companies’ product-information estates

A new benchmark maps 100 UK prescription medicine companies across five maturity bands and finds a market at very different stages of digital development

Where translation falls short in practice

Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.

The words around health matter

Press Releases | June 4, 2026 | Mednet

The language used in healthcare can influence how people perceive their health, feel about themselves, and engage with treatments. Whole-person communication can help reduce stigma and support better real-world healthcare...